TherapeuticsMD, Inc.
TXMDNasdaqHealthcare · Pharmaceutical Preparations · NV · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $3.0M | $1.8M | $300,000 | $70.0M | $2.6M | $12.3M |
| Operating income | −$4.4M | −$6.1M | −$8.5M | $1.2M | −$79.6M | −$50.9M |
| Net income | −$569,000 | −$2.2M | −$10.3M | $112.0M | −$172.4M | −$56.8M |
| Total assets | $37.7M | $38.8M | $43.3M | $90.5M | $169.5M | $181.6M |
| Total liabilities | $10.8M | $11.5M | $14.0M | $55.3M | $263.1M | $305.6M |
| Equity | $26.9M | $27.4M | $29.3M | $35.1M | −$93.6M | −$124.0M |
| EPS (diluted) | $-0.05 | $-0.19 | $-0.98 | $11.96 | $-21.66 | — |
| Shares out. | 11.6M | 11.5M | 10.0M | 433.4M | 387.8M | 271.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −145.3%
- Net margin
- −18.8%
- Return on equity
- −2.1%
- Return on assets
- −1.5%
- Return on capital (ROCE)
- −13.4%
- Liabilities / assets
- 28.6%
- Debt / equity
- 0.40×
- Book value / share
- $2.32
- Revenue growth (YoY)
- 71.6%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -78.93distress
- Accruals / assets
- −8.0%clean
- Piotroski F-Score
- 7/9strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 2 warning● 4 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Apr 1, 2026
- NT 10-Kmissed a reporting deadline ↗Mar 31, 2023
- NT 10-Qmissed a reporting deadline ↗May 16, 2011
- NT 10-Kmissed a reporting deadline ↗Mar 31, 2011
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Baselake Partners, LpPassive (13G)Apr 6, 2026
- Clearline Capital LpPassive (13G)Feb 12, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 53,083 | 2.3 | -6.5% |
| Apr 30, 2026 | 56,765 | 2.7 | +8.8% |
| Apr 15, 2026 | 52,193 | 2.1 | +8.1% |
| Mar 31, 2026 | 48,285 | 2.3 | +1.6% |
| Mar 13, 2026 | 47,542 | 2.0 | +5.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operations · Regulation FD disclosureMay 12, 2026
- Results of operations · Regulation FD disclosureMar 30, 2026
- Changed auditorJan 21, 2026
- Shareholder voteDec 16, 2025
- Results of operations · Regulation FD disclosureNov 13, 2025
- Results of operations · Regulation FD disclosureAug 12, 2025
- Results of operations · Regulation FD disclosureMay 13, 2025
- Other material eventApr 9, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 10-QQUARTERLY REPORTMay 12, 2026
- 8-KCURRENT REPORTMay 12, 2026
- SCHEDULE 13GApr 6, 2026
- 10-K/AANNUAL REPORTApr 1, 2026
- NT 10-KNOTIFICATION OF LATE FILINGApr 1, 2026
- 8-KCURRENT REPORTMar 30, 2026
- 10-KANNUAL REPORTMar 30, 2026
- 8-KCURRENT REPORTJan 21, 2026
- 4Dec 29, 2025
- 8-KCURRENT REPORTDec 16, 2025
- 8-KCURRENT REPORTNov 13, 2025
- 10-QQUARTERLY REPORTNov 12, 2025
- 4Nov 5, 2025
- 4Nov 5, 2025
- 4Nov 5, 2025
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.